What is HC Wainwright’s Estimate for PolyPid Q1 Earnings?

PolyPid Ltd. (NASDAQ:PYPD) – Stock analysts at HC Wainwright issued their Q1 2026 earnings estimates for shares of PolyPid in a research note issued to investors on Wednesday, February 11th. HC Wainwright analyst B. Folkes expects that the company will earn ($0.49) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $13.00 target price on the stock. The consensus estimate for PolyPid’s current full-year earnings is ($1.79) per share. HC Wainwright also issued estimates for PolyPid’s Q2 2026 earnings at ($0.47) EPS, Q3 2026 earnings at ($0.39) EPS, Q4 2026 earnings at ($0.37) EPS, FY2026 earnings at ($1.69) EPS, FY2027 earnings at ($0.68) EPS and FY2029 earnings at $1.90 EPS.

Several other research analysts also recently issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of PolyPid in a research note on Monday, December 29th. Roth Mkm decreased their price objective on shares of PolyPid from $10.00 to $9.00 and set a “buy” rating for the company in a report on Thursday, November 13th. Wall Street Zen raised PolyPid from a “sell” rating to a “hold” rating in a research report on Sunday, November 16th. Finally, Citigroup reissued a “market outperform” rating on shares of PolyPid in a report on Monday, December 1st. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $12.25.

PolyPid Stock Down 3.5%

Shares of PYPD stock opened at $4.43 on Friday. PolyPid has a 12-month low of $2.30 and a 12-month high of $5.12. The business has a 50-day moving average price of $4.37 and a two-hundred day moving average price of $3.81. The firm has a market cap of $70.44 million, a P/E ratio of -1.96 and a beta of 1.52.

PolyPid (NASDAQ:PYPD) last released its earnings results on Wednesday, February 11th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.07).

Institutional Trading of PolyPid

A number of hedge funds have recently bought and sold shares of PYPD. BNP Paribas Financial Markets lifted its holdings in PolyPid by 56.1% in the third quarter. BNP Paribas Financial Markets now owns 9,734 shares of the company’s stock valued at $32,000 after acquiring an additional 3,500 shares during the period. HighTower Advisors LLC bought a new position in shares of PolyPid in the 4th quarter worth approximately $44,000. Jane Street Group LLC purchased a new position in shares of PolyPid in the fourth quarter worth approximately $66,000. Lumbard & Kellner LLC purchased a new position in shares of PolyPid in the second quarter worth approximately $135,000. Finally, AIGH Capital Management LLC grew its position in PolyPid by 27.0% during the second quarter. AIGH Capital Management LLC now owns 1,194,108 shares of the company’s stock valued at $4,215,000 after buying an additional 253,727 shares during the period. Hedge funds and other institutional investors own 26.47% of the company’s stock.

More PolyPid News

Here are the key news stories impacting PolyPid this week:

• Positive Sentiment: HC Wainwright maintains a “Buy” rating and a $13 price target and models significant long‑term upside (FY2028 and FY2030 estimates were raised to positive territory), which supports a bullish narrative for PYPD’s eventual commercial prospects.
• Positive Sentiment: Management’s Q4 earnings call was described as upbeat and flagged a potentially material 2026 catalyst that investors may view as a near‑term growth trigger. PolyPid Earnings Call Flags Big 2026 Catalyst
• Neutral Sentiment: Full Q4 2025 earnings call transcript and highlight coverage are available for investors who want details on pipeline timing, trial milestones and cash guidance; these provide context but may not move the stock until the 2026 catalyst is clarified. Q4 2025 Earnings Call Highlights Q4 2025 Earnings Call Transcript
• Negative Sentiment: HC Wainwright materially lowered FY2026 EPS estimates (now forecasting a larger loss: -$1.69 vs prior -$1.46) and trimmed FY2029 slightly, signaling worse near‑term profitability than previously expected — a negative for short‑term sentiment.
• Negative Sentiment: PolyPid missed Q4 EPS expectations (reported -$0.41 vs consensus -$0.34), underscoring current cash‑burn/loss trends that weigh on the share price until clinical or commercial catalysts materialize. Earnings Call Transcript

About PolyPid

PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.